Catalog No. |
TD-HS856096 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer |
Expression system |
Mammalian Cells |
Species |
Human |
Clonality |
Monoclonal |
Target |
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1 |
Endotoxin level |
Please contact with the lab for this information. |
Purity |
>95% as determined by SDS-PAGE. |
Purification |
Protein A/G purified from cell culture supernatant. |
Accession |
Q16552 & P01375 |
Form |
Liquid |
Storage buffer |
0.01M PBS, pH 7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names |
Bispecific, A-1230717, ABT-122, CAS: 1791410-27-9 |
Background |
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research. |
Note |
For research use only. Not suitable for clinical or therapeutic use. |